Skip to content

US · NNOX · MEDICAL - DEVICES

Nano-X Imaging Ltd. (NNOX) intrinsic value and stock valuation

$0.23as of 2026-11-21 · Mkt cap 69.6M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nano-X Imaging Ltd. DCF and intrinsic value

InvestorsCraft values NNOX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NNOX’s statements →

Nano-X Imaging Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Neve Ilan 9085000 nanox.vision

How the business is doing

Fiscal 2018–2025, USD

Revenue
$13M
20182025
Net income
-$-75.02M
20182025
Free cash flow
-$-45M
20182025
Total equity
$139.7M-9.5% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$13M$11.3M$9.9M$8.58M$1.3M
Operating income-$-60.7M-$-56.75M-$-62.59M-$-109.71M-$-61.56M
Net income-$-75.02M-$-53.52M-$-60.78M-$-105.24M-$-61.8M
EPSd-$-1.16M-$-913K-$-1.08M-$-2.01M-$-1.28M
Operating cash flow-$-40.79M-$-36.6M-$-44.78M-$-43.38M-$-38.07M
Capital expenditure-$-4.21M-$-2.77M-$-3.3M-$-7.17M-$-23.16M
Free cash flow-$-45M-$-39.37M-$-48.08M-$-50.56M-$-61.23M
Total assets$162.2M$210M$218.7M$253.9M$363.2M
Total debt$7.85M$7.45M$8.4M$4.62M$5.77M
Net debt-$-41.3M-$-31.86M-$-47.98M-$-33.84M-$-60.87M
Total equity$139.7M$189.1M$195.5M$216.7M$292.2M
Cash and short-term investments$59.6M$73.2M$82.4M$77.6M$88.7M
Income statement
20252024202320222021
Revenue$13M$11.3M$9.9M$8.58M$1.3M
Cost of revenue$25.8M$21.9M$16.5M$15.5M$2.82M
Gross profit-$-12.79M-$-10.61M-$-6.59M-$-6.88M-$-1.51M
Research and development expenses$19.2M$20.2M$26.1M$26.5M$17.1M
Selling, general and administrative expenses$27.1M$25.8M$28.4M$45.6M$41.7M
Other expenses$1.58M$210K$1.55M$190K$1.18M
Operating expenses$47.9M$46.1M$56M$72.3M$60.1M
Cost and expenses$73.7M$68M$72.5M$87.8M$62.9M
Interest income$1.42M$2.87M$1.65M$790K$0.00
Interest expense$0.00$0.00$0.00$0.00$290K
Depreciation and amortization$11.7M$11.7M$11.8M$11.5M$2.29M
Ebitda-$-49M-$-45.01M-$-47.69M-$-75.7M-$-59.27M
Operating income-$-60.7M-$-56.75M-$-62.59M-$-109.71M-$-61.56M
Total other income/expenses, net-$-16.11M$2.87M$1.47M-$-14.67M-$-290K
Income before tax-$-76.81M-$-53.87M-$-61.12M-$-108.92M-$-61.85M
Income tax expense-$-1.79M-$-360K-$-340K-$-3.68M-$-50K
Net income-$-75.02M-$-53.52M-$-60.78M-$-105.24M-$-61.8M
Weighted average shares outstanding$64.8M$58.6M$56.4M$52.2M$48.2M
Weighted average diluted shares outstanding$64.8M$58.6M$56.4M$52.2M$48.2M
Balance sheet
20252024202320222021
Cash and short-term investments$59.6M$73.2M$82.4M$77.6M$88.7M
Net receivables$2.01M$1.8M$1.48M$980K$1.05M
Inventory$3.07M$1.49M$2.36M$2.41M$3.13M
Total current assets$66.8M$78.7M$88.6M$82.5M$94.9M
Property, plant and equipment, net$33.2M$49.2M$46.9M$44.7M$39.2M
Goodwill and intangible assets$60.2M$70M$80.6M$98.6M$160.1M
Long-term investments$360K$340K$330K$25.2M$67.8M
Total non-current assets$95.4M$131.3M$130M$171.5M$268.3M
Total assets$162.2M$210M$218.7M$253.9M$363.2M
Accounts payable$2.89M$2.21M$3.3M$3.62M$3.13M
Short-term debt$4.09M$3.81M$4.35M$740K$1.03M
Deferred revenue$530K$140K$540K$180K$250K
Total current liabilities$16.9M$14M$15.5M$25.1M$52.8M
Long-term debt$3.77M$3.64M$4.04M$3.88M$4.75M
Deferred revenue, non-current$20K$0.00$0.00$400K$410K
Total non-current liabilities$5.54M$6.91M$7.61M$12.2M$18.3M
Capital lease obligations$4.71M$4.38M$4.91M$1.14M$1.83M
Total liabilities$22.4M$20.9M$23.1M$37.3M$71M
Common stock$200K$180K$170K$160K$150K
Retained earnings-$-448.77M-$-373.75M-$-320.23M-$-259.46M-$-146.21M
Accumulated other comprehensive income (loss)-$0.00-$0.00-$-300K-$-1.97M-$-610K
Total equity$139.7M$189.1M$195.5M$216.7M$292.2M
Total investments$10.8M$34.2M$26.3M$64.4M$89.9M
Total debt$7.85M$7.45M$8.4M$4.62M$5.77M
Net debt-$-41.3M-$-31.86M-$-47.98M-$-33.84M-$-60.87M
Cash flow statement
20252024202320222021
Net income-$-75.02M-$-53.52M-$-60.78M-$-105.24M-$-61.8M
Depreciation and amortization$11.7M$11.7M$11.8M$11.5M$2.29M
Stock-based compensation$4.19M$7.26M$6.84M$18.6M$18.8M
Change in working capital$2.77M-$-1.13M-$-7.48M-$-16.95M$2.75M
Accounts receivable$110K-$-320K-$-510K$70K-$-40K
Inventory-$-330K-$-280K$0.00$0.00$860K
Accounts payable$290K-$-1.32M-$-150K$470K$1.72M
Net cash provided by operating activities-$-40.79M-$-36.6M-$-44.78M-$-43.38M-$-38.07M
Investments in property, plant and equipment-$-4.21M-$-2.77M-$-3.3M-$-7.17M-$-23.16M
Acquisitions, net$0.00$0.00$0.00$1.01M-$-2.86M
Net cash used for investing activities$29.4M-$-20.05M$35.4M$14.6M-$-116.32M
Common stock issued$21.4M$37.8M$27.1M$950K$3.58M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$21.4M$39.5M$27.3M$800K$7.38M
Net change in cash$9.85M-$-17.07M$17.9M-$-28.24M-$-147.01M
Cash at end of period$49.2M$39.3M$56.4M$38.5M$66.8M
Operating cash flow-$-40.79M-$-36.6M-$-44.78M-$-43.38M-$-38.07M
Capital expenditure-$-4.21M-$-2.77M-$-3.3M-$-7.17M-$-23.16M
Free cash flow-$-45M-$-39.37M-$-48.08M-$-50.56M-$-61.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nano-X Imaging Ltd.

        Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.

        CEO
        Erez I. Meltzer
        Employees
        197
        Beta
        1.23

        Explore

        Frequently asked questions

        What is the intrinsic value of Nano-X Imaging Ltd. (NNOX)?

        InvestorsCraft does not currently publish an intrinsic value for NNOX. How the IC value is calculated.

        Is NNOX undervalued?

        InvestorsCraft does not publish an undervaluation signal for NNOX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.